Based on this notion, acetylcholinesterase inhibitors (AChEIs) have been used in the past three decades to treat AD, owing to their ability to block the function of acetylcholinesterase (AChE), an enzyme that hydrolyses ACh at the synaptic cleft into acetate and choline. This evidence concerns the gene ACHE and Alzheimer disease.